ArticleThe New England journal of medicine2013
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma.
Article in The New England journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target.Experimental hematology · 2014Trial
- Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy.Clinical and molecular hepatology · 2026Review
- The role of AP2M1 in oncofetal characteristics: integrative in silico, in vitro, and in vivo analyses using zebrafish models.European journal of medical research · 2025Article
- Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC.Communications chemistry · 2025Article
- SALL4 is a CRL3Cell death and differentiation · 2024Article
- SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.International journal of molecular sciences · 2022Review
- Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4.Nature communications · 2021Article
- Expression and clinical value of SALL4 in renal cell carcinomas.Molecular medicine reports · 2020Article
- Article
- miR-103/miR-195/miR-15b Regulate SALL4 and Inhibit Proliferation and Migration in Glioma.Molecules (Basel, Switzerland) · 2018Article
- Identification of sequence polymorphisms in the mitochondrial cytochrome c oxidase genes as risk factors for hepatocellular carcinoma.Journal of clinical laboratory analysis · 2018Article
- Bivalent Epigenetic Control of Oncofetal Gene Expression in Cancer.Molecular and cellular biology · 2017Review
- SALL4 promotes glycolysis and chromatin remodeling via modulating HP1α-Glut1 pathway.Oncogene · 2017Article
- Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer.Oncotarget · 2017Review
- Stemness-Related Markers in Cancer.Cancer translational medicine · 2017Article
- Targeting SALL4 by entinostat in lung cancer.Oncotarget · 2016Article
- Review
- Expression and clinical significance of SALL4 and β-catenin in colorectal cancer.Journal of molecular histology · 2016Article
- Importance of SALL4 in the development and prognosis of hepatocellular carcinoma.World journal of gastroenterology · 2016Article
- Knockdown of Sall4 inhibits intrahepatic cholangiocarcinoma cell migration and invasion in ICC-9810 cells.OncoTargets and therapy · 2016Article
Corrections and comments
- Comment on
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24047068What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.